US 12,116,371 B2
Substituted pyridines as irreversible inhibitors of menin-MLL interaction
Thomas Butler, Redwood City, CA (US); Jim Palmer, Warrandyte (AU); Ravi Upasani, San Jose, CA (US); Matthew Welsch, New Haven, CT (US); Sridhar Vempati, Edison, NJ (US); Brendan Kelly, Castlecomer (IE); and Edward Painter, Chappaqua, NY (US)
Assigned to BIOMEA FUSION, INC., Redwood City, CA (US)
Filed by BIOMEA FUSION, INC., Redwood City, CA (US)
Filed on Jul. 31, 2023, as Appl. No. 18/228,602.
Application 18/094,929 is a division of application No. 17/352,146, filed on Jun. 18, 2021, granted, now 11,702,421, issued on Jul. 18, 2023.
Application 18/228,602 is a continuation of application No. 18/094,929, filed on Jan. 9, 2023.
Application 17/352,146 is a continuation of application No. 16/732,226, filed on Dec. 31, 2019, granted, now 11,084,825, issued on Aug. 10, 2021.
Claims priority of provisional application 62/786,842, filed on Dec. 31, 2018.
Prior Publication US 2023/0391784 A1, Dec. 7, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/4427 (2006.01); C07D 401/04 (2006.01); C07D 401/06 (2006.01); C07D 401/14 (2006.01); C07D 471/04 (2006.01); C07D 487/04 (2006.01)
CPC C07D 487/04 (2013.01) [C07D 401/04 (2013.01); C07D 401/06 (2013.01)] 14 Claims
 
1. A compound according to formula (XVI):

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt or stereoisomer thereof.
 
2. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of the compound according to claim 1, or a pharmaceutically acceptable salt or stereoisomer thereof.